| PESUC21 | Life years gained with improved HIV care among non-Hispanic Black and White people who have ever injected drugs (PWID) with HIV: a modeling study | Poster exhibition | Modelling the impact of service models on the HIV epidemic |
| PESUC20 | Projection of age of people living with HIV and time since ART initiation in high-income countries in 2030: estimates for France | Poster exhibition | Modelling future healthcare needs |
| PESUC19 | Assessing levels of provincial HIV virological suppression in the public health sector in South Africa during the COVID-19 pandemic | Poster exhibition | Monitoring and evaluation of health systems along the HIV cascade |
| PESUC18 | Disproportionate HIV burden among key populations in sub-Saharan Africa: national estimates of population size, HIV prevalence, and ART coverage | Poster exhibition | Surveillance of HIV in key populations |
| PESUB26 | The first-in-human clinical trial of STP0404, a novel potent HIV-1 allosteric integrase inhibitor | Poster exhibition | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| PESUB25 | Bridging the gap between patient perceptions and delivered care among people living with HIV in the Asian region | Poster exhibition | Adherence |
| PESUB24 | A study evaluating the safety, tolerability, and pharmacokinetics of a high-concentration (CAB 400mg/ml) cabotegravir long-acting injectable formulation following subcutaneous and intramuscular administration in healthy adult participants | Poster exhibition | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| PESUB23 | Simulations for once weekly dosing of oral lenacapavir | Poster exhibition | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| PESUB22 | Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus Phase 2/3 regimen | Poster exhibition | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring |
| PESUB21 | Efficacy and safety of switching to Dolutegravir/Lamivudine (DTG/3TC) in treatment-experienced, virologically suppressed PLHIV aged '¥50 years: pooled results from the TANGO and SALSA Studies | Poster exhibition | Regimen simplification and switch studies |